Biologics International Corporation

Biologics International Corporation
Name	Biologics International Corporation
Type	Public
Industry	Biotechnology
Founded	1995
Headquarters	Schaumburg, Illinois, United States
Key people	David Young (CEO)
Products	Biosimilars, biologics contract services
Revenue	(varied)
Num employees	(varied)

Biologics International Corporation is an American biotechnology company focused on development, testing, and manufacturing of biologic therapeutics and biosimilars. The company has operated facilities for clinical and regulatory support, offering analytical services, contract manufacturing, and product development. Its activities intersect with major pharmaceutical, regulatory, and legal institutions internationally.

History

Biologics International Corporation was founded in the mid-1990s during a period of expansion in the biotechnology sector that included companies such as Genentech, Amgen, Biogen, Wyeth, and Eli Lilly and Company. Early growth paralleled events like the Human Genome Project and the rise of biologic therapeutics exemplified by products from Roche and Novartis. The company expanded its laboratory and manufacturing footprint amid consolidation waves that involved firms such as Mylan and Teva Pharmaceutical Industries. Strategic milestones aligned with regulatory developments from agencies including the U.S. Food and Drug Administration and the European Medicines Agency, and with intellectual property disputes reminiscent of cases involving AbbVie and Amgen.

Products and Services

The company offers analytical characterization, quality control testing, stability studies, and contract development and manufacturing services comparable to offerings from contract research organizations like Charles River Laboratories and LabCorp. Its product portfolio has included biosimilar candidates intended to compete in therapeutic areas served by products from Johnson & Johnson, Pfizer, Merck & Co., Sanofi, and Bristol Myers Squibb. Services also target clients developing monoclonal antibodies, recombinant proteins, and vaccines—technologies central to companies such as Moderna and GSK.

Research and Development

Research programs focused on formulation development, analytical method validation, and biosimilar comparability studies, fields where methodologies from academic institutions like Massachusetts Institute of Technology and Harvard University influence industrial practice. R&D collaborations and contract projects connected the firm to biotechnology clusters in regions including Silicon Valley, Boston, Massachusetts, and the Research Triangle near Raleigh, North Carolina. Scientific outputs addressed challenges similar to those tackled by researchers at National Institutes of Health, Dana–Farber Cancer Institute, and St. Jude Children's Research Hospital.

Regulatory and Legal Issues

Regulatory interactions involved submissions and correspondence with authorities such as the U.S. Food and Drug Administration, the European Medicines Agency, and national agencies in markets such as Canada and Japan. The company has navigated legal matters typical in the biotechnology sector, including patent disputes and contract litigation comparable to high-profile cases involving Teva Pharmaceutical Industries and Gilead Sciences. Compliance and inspection activities referenced standards from organizations like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and guidance associated with legislation including the Biologics Price Competition and Innovation Act.

Corporate Structure and Ownership

The corporate structure reflects a public-company model with executive leadership and a board of directors, paralleling governance structures at firms such as Eli Lilly and Company and Baxter International. Shareholder relations and market listings brought interaction with capital markets infrastructure including exchanges like the NASDAQ and institutions such as Goldman Sachs and JPMorgan Chase. Ownership changes and strategic transactions in the sector have involved private equity firms and strategic acquirers comparable to activity by Bain Capital and KKR in life sciences.

Financial Performance and Market Presence

Financial performance has been shaped by revenue from contract research and manufacturing, development-stage program valuations, and reimbursements tied to products in development—factors similar to revenue models at Catalent and Lonza Group. Market presence included partnerships and client relationships with biotechnology and pharmaceutical companies across North America, Europe, and Asia, mirroring global networks maintained by Pfizer and Novartis. The firm's valuation dynamics were influenced by investment trends affecting companies such as Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and Biomarin Pharmaceutical.

Category:Biotechnology companies